As global markets grapple with economic uncertainty and inflation concerns, Asian stocks present a unique opportunity for investors seeking growth potential amidst volatility. In this environment, companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those closest to the business and may offer resilience in challenging times.

Top 10 Growth Companies With High Insider Ownership In Asia

Name	Insider Ownership	Earnings Growth
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)	23.3%	26%
Sineng ElectricLtd (SZSE:300827)	36.3%	41.4%
Seojin SystemLtd (KOSDAQ:A178320)	32.1%	39.3%
Quick Intelligent EquipmentLtd (SHSE:603203)	34.2%	35.6%
Laopu Gold (SEHK:6181)	36.4%	47.2%
Global Tax Free (KOSDAQ:A204620)	21.8%	89.3%
Zhejiang Leapmotor Technology (SEHK:9863)	15.2%	61.9%
Fulin Precision (SZSE:300432)	13.6%	78.6%
Synspective (TSE:290A)	13.2%	37.4%
Ascentage Pharma Group International (SEHK:6855)	17.9%	83.6%

Click here to see the full list of 656 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Runben Biotechnology (SHSE:603193)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Runben Biotechnology Co., Ltd. focuses on the research, production, and sale of mosquito repellent products, baby care products, and essential oil products with a market cap of approximately CN¥14.09 billion.

Operations: The company's revenue is primarily derived from personal products, totaling CN¥1.25 billion.

Insider Ownership: 30.1%

Runben Biotechnology demonstrates strong growth potential, with earnings forecasted to grow 22.44% annually and revenue expected to increase by 24.8% per year, outpacing the Chinese market's growth rate. Despite this promising outlook, its Return on Equity is projected to remain modest at 17%. The company has not shown substantial insider trading activity in the past three months. Earnings grew significantly by 46.3% last year, indicating robust recent performance.

• Click here and access our complete growth analysis report to understand the dynamics of Runben Biotechnology.
• In light of our recent valuation report, it seems possible that Runben Biotechnology is trading beyond its estimated value.

Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266)

Simply Wall St Growth Rating: ★★★★★★

Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHSE:688266) is a company focused on the research, development, and commercialization of innovative pharmaceuticals, with a market cap of approximately CN¥25.99 billion.

Operations: The company generates revenue primarily from its pharmaceuticals segment, which amounts to CN¥533.91 million.

Insider Ownership: 29.4%

Suzhou Zelgen Biopharmaceuticals is poised for significant growth, with earnings forecasted to increase by 134.61% annually and revenue expected to rise by 57.5% per year, surpassing the Chinese market's growth rate. The company is anticipated to become profitable within three years and boasts a high future Return on Equity of 20.2%. Recent financial results show improved performance with sales reaching CNY 533.91 million and a reduced net loss of CNY 136.22 million compared to the previous year.

• Delve into the full analysis future growth report here for a deeper understanding of Suzhou Zelgen BiopharmaceuticalsLtd.
• Our comprehensive valuation report raises the possibility that Suzhou Zelgen BiopharmaceuticalsLtd is priced higher than what may be justified by its financials.

Jiangsu Huahong Technology (SZSE:002645)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Jiangsu Huahong Technology Co., Ltd. operates in the research, development, manufacturing, marketing, and servicing of renewable resource processing equipment both in China and internationally, with a market cap of CN¥5.51 billion.

Operations: The company's revenue is primarily derived from its activities in the research, development, manufacturing, marketing, and servicing of renewable resource processing equipment both domestically and internationally.

Insider Ownership: 18.1%

Jiangsu Huahong Technology is positioned for growth, with earnings projected to increase by 88.7% annually and revenue expected to grow at 23% per year, outpacing the Chinese market's average. The company is anticipated to turn profitable within three years. Despite a low future Return on Equity of 7.6%, it trades at good value relative to peers. A recent shareholders meeting addressed reallocating surplus funds from completed projects to bolster working capital.

• Navigate through the intricacies of Jiangsu Huahong Technology with our comprehensive analyst estimates report here.
• The analysis detailed in our Jiangsu Huahong Technology valuation report hints at an deflated share price compared to its estimated value.

Make It Happen

• Get an in-depth perspective on all 656 Fast Growing Asian Companies With High Insider Ownership by using our screener here.
• Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.